Corcept Therapeutics (CORT) Drug Pipeline

The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

Corcept Therapeutics CORT is currently developing the following drugs: Miricorilant, Nivolumab, Nenocorilant 200 Mg, Nenocorilant 300 Mg, Nenocorilant 400 Mg, Cort125236, Miricorilant Treatment A, Miricorilant Treatment B, Miricorilant Treatment C, Miricorilant Treatment D, Relacorilant 150 Mg Once Daily, Nab-Paclitaxel 100 Mg/M^2, Gemcitabine 1000 Mg/M^2, Cort125134, Dazucorilant, Nab-Paclitaxel 80 Mg/M^2, Relacorilant 150 Mg Once Daily, Bevacizumab 10 Mg/Kg, Itraconazole, Dazucorilant, Cort125134 150 Mg, Cort125134 250 Mg, Cort125134 Dose To Be Determined, Cort125134, Relacorilant, Relacorilant Under Fasted Conditions, Relacorilant After A High-Fat Meal, Relacorilant After A Low-Fat Meal, Mifepristone 300 Mg [Korlym], Fluvoxamine, Miricorilant, Dazucorilant 300 Mg, Dazucorilant 150 Mg, Relacorilant, Dabigatran Etexilate, Nab-Paclitaxel 80 Mg/M^2, Relacorilant 150 Mg Once Daily, Nab-Paclitaxel 100 Mg/M^2, Miricorilant 150 Mg, Miricorilant 100 Mg, Miricorilant 50 Mg, Miricorilant 10 Mg, Cort113176, [14C]-Cort113176, Prednisone, Cort125236, Moxifloxacin, Relacorilant, Miricorilant 300 Mg Tablets, Miricorilant 150 Mg Tablets, Prednisone, Cort125329 Lipid Capsule Formulation, Miricorlilant, Pembrolizumab, Relacorilant, Nab-Paclitaxel, Relacorilant, 100 Mg And 25 Mg, Prednisone, Cort113176 Lipid Capsule Formulation, 14C-Cort125281, Cort118335 Oral, 14C-Cort118335 Intravenous, 14C-Cort118335 Oral, Olanzapine, Cort118335, Nab-Paclitaxel, Relacorilant. These drug candidates are in various stages of clinical development as the company works toward FDA approval.